T. Rowe Price Investment Management, Inc. Immunovant, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Immunovant, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 5,894,824 shares of IMVT stock, worth $162 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
5,894,824
Previous 5,117,234
15.2%
Holding current value
$162 Million
Previous $127 Million
20.52%
% of portfolio
0.07%
Previous 0.08%
Shares
4 transactions
Others Institutions Holding IMVT
# of Institutions
219Shares Held
78.2MCall Options Held
1.5MPut Options Held
1.55M-
Deep Track Capital, LP Greenwich, CT9.5MShares$261 Million9.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.94MShares$191 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.79% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.5MShares$124 Million1.89% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...